Novartis AG, headquartered in Basel, Switzerland, is a leading global pharmaceutical corporation renowned for its innovative medicines and significant contributions to healthcare. Formed in 1996 from the merger of Ciba-Geigy and Sandoz, Novartis focuses on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. The company boasts a diverse product portfolio, including Gleevec for leukemia and Cosentyx for psoriasis. In 2024, Novartis continued its growth through strategic acquisitions, such as MorphoSys AG, and advancements in its pharmaceutical and radioligand therapy pipelines.